The content on this site is intended for healthcare professionals only
Dr Elena Elimova speaks to ecancer about the HERIZONGEA-01 trial.
In this trial, zanidatamab-based regimens significantly improved progression-free survival compared with trastuzumab plus chemotherapy in previously untreated HER2-positive metastatic gastric and gastroesophageal adenocarcinoma.
Zanidatamab combined with tislelizumab and chemotherapy also demonstrated a statistically significant and clinically meaningful overall survival benefit, with durable efficacy across key subgroups regardless of PD-L1 status.
Safety was manageable and consistent with known profiles, with no new safety signals identified.
These results support zanidatamab as a potential new first-line standard of care for HER2-positive metastatic gastroesophageal adenocarcinoma.
Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer
Zolbetuximab plus nivolumab and chemotherapy shows promising responses in CLDN18.2-positive metastatic gastric cancer
Consolidation treatment delays do not compromise survival in MRD-negative adult ALL
Black patients show inferior survival despite similar cytogenetics and treatment response
Rocbrutinib shows strong responses in resistant CLL, including BTKi- and venetoclax-exposed patients
ESMO 2025: Latest developments in endometrial cancer
Best practice in precision medicine for prostate cancer
Visugromab plus nivolumab significantly increases pathologic response in muscle-invasive bladder cancer
Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC
